CYTK Cytokinetics, Incorporated - Common Stock
$76,55
Kurs · Aug 20, 2026
Fundamentaldaten per Aug 6, 2026
52W-Spanne
$35–$88
78% of range
Analystenbewertung
BUY
28 analysts
Kursziel
$110
+44% upside
P/E (TTM)
-11.7
ROE
152.7%
Nettogewinnmarge
-891.6%
Über Cytokinetics, Incorporated - Common Stock Unternehmensübersicht von Wikipedia
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
Mehr lesen
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
History
Cytokinetics was founded in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S.B. Goldstein, four scientists at Stanford, UCSD, and UCSF. Operations began in 1998.
Initially, Cytokinetics focused on the possible pharmacological targets and areas of application of drugs based on cytoskeletal proteins. Eventually, the company narrowed its focus to the mechanics of muscle biology. Cytokinetics develops muscle activators and muscle inhibitors to improve muscle function in patients with cardiovascular and neuromuscular diseases.
In 2004 the company completed its initial public offering (IPO).
In January 2007, Cytokinetics named Robert I. Blum as president and CEO. Prior to this, Blum has been involved in the company since its founding, with roles in business development, corporate development and R&D.
In 2013, Cytokinetics finalized a licensing and discovery deal with Astellas to research treatment for muscle weakness and fatigue.
In July 2020, Ji Xing Pharmaceuticals signed a financing deal with Cytokinetics, which included the rights to commercialize the drug designed to treat hypertrophic cardiomyopathies, aficamten, in China and certain neighboring regions.
Products
Omecamtiv mecarbil is a cardiac muscle activator for the potential treatment of heart failure. In May 2020, omecamtiv mecarbil was granted fast track designation by the FDA for the treatment of chronic HF with reduced ejection fraction. Amgen purchased an option on omecamtiv mecarbil in 2006, and the two companies extended their partnership several times. In June 2013, Cytokinetics and Amgen expanded their licensing deal for omecamtiv mecarbil to include Japan. In November 2020 Amgen elected to terminate the collaboration, effective May 20, 2021, and Cytokinetics regained worldwide rights to develop and commercialize omecamtiv mecarbil.
Reldesemtiv (previously known as CK-2127107) is a next-generation fast skeletal muscle troponin activator (FSTA) that has undergone clinical trials for ALS.
Aficamten (previously known as CK-3773274) is an oral, small-molecule myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM).
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
CYTK Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$76.55
Marktkapitalisierung
$9.41B
P/E (TTM)
-11.7
EPS (TTM)
$-6.54
Umsatz (TTM)
$88M
Dividendenrendite
—
ROE
152.7%
Verschuldungsgrad
-0.4
52W-Spanne
$35 – $88
CYTK Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
$88M
2016-12-31
→
2025-12-31
EPS
$-6.54
2016-12-31
→
2025-12-31
Freier Cashflow
$-535M
2016-12-31
→
2025-12-31
Margen
-891.6%
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
CYTK
Peer-Median
P/E (TTM)
-11.7
28.5
P/S (TTM) (K/V (TTM))
106.9
20.1
P/B (K/B)
-14.3
12.9
EV / EBITDA
-15.9
—
Price / FCF (Kurs / FCF)
-17.6
—
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
CYTK
Peer-Median
Operating Margin (Betriebsgewinnmarge)
-695.4%
—
Net Profit Margin (Nettogewinnmarge)
-891.6%
-48.4%
ROA
-55.5%
-28.4%
ROE
152.7%
-49.2%
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
CYTK
Peer-Median
Debt / Equity (Fremdkapital / Eigenkapital)
-0.4
—
Current Ratio (Liquiditätsgrad)
4.5
5.0
Quick Ratio
0.7
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
CYTK
Peer-Median
Revenue YoY (Umsatz YoY)
376.6%
—
Revenue CAGR 3Y (Umsatz CAGR 3J)
-2.4%
—
Revenue CAGR 5Y (Umsatz CAGR 5J)
9.5%
—
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
CYTK
Peer-Median
CYTK Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
28 Analysten
- Starker Kauf 6 21,4%
- Kauf 19 67,9%
- Halten 3 10,7%
- Verkauf 0 0,0%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
20 Analysten · 2026-08-18
Median
$107.50
← Unter allen Zielen
$76.55
Tief
$85.00
Hoch
$146.00
Median-Ziel
$107.50
+40,4%
Mittelwert-Ziel
$109.90
+43,6%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-0.08%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 30. Juni 2026 | $-1.50 | $-1.67 | 0.17% |
| 31. März 2026 | $-1.67 | $-1.69 | 0.02% |
| 31. Dezember 2025 | $-1.50 | $-1.49 | -0.01% |
| 30. September 2025 | $-2.55 | $-1.61 | -0.94% |
| 30. Juni 2025 | $-1.12 | $-1.41 | 0.28% |
| 31. März 2025 | $-1.39 | $-1.41 | 0.02% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | — |
| BMRN | $11.43B | 33.0 | 12.9% | 10.8% | 5.8% | — |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | — |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
| KYMR | $6.33B | -21.1 | -16.7% | -794.0% | -24.4% | — |
| APGE | $5.16B | -17.9 | — | — | — | — |
| PRAX | $7.43B | -21.9 | 249.5% | — | -47.3% | — |
| KRYS | $7.20B | 36.0 | 33.9% | 52.6% | 18.1% | — |
| SMMT | $13.56B | -12.1 | — | — | -235.1% | — |
| IONS | $12.92B | -33.2 | — | — | -68.1% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 16
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| R&D Expense | $416M | $339M | $330M | $241M | $160M | $97M | $86M | $89M | $90M | $60M | $46M | $44M | |
| SG&A Expense | $284M | $215M | $174M | $178M | $97M | $53M | $40M | $31M | $36M | $28M | $20M | $17M | |
| Operating Expenses | $700M | $555M | $504M | $419M | $257M | $150M | $126M | $120M | $127M | $88M | $66M | $62M | |
| Operating Income | $-612M | $-536M | $-496M | $-324M | $-186M | $-94M | $-99M | $-89M | $-113M | $19M | $-37M | $-15M | |
| Interest Expense | $46M | $38M | $28M | $19M | $16M | $16M | $7M | $4M | $3M | $3M | $268.0K | $0 | |
| Interest Income | · | · | · | $11M | $1M | $5M | $4M | $4M | · | $449.0K | $156.0K | $101.0K | |
| Other Non-op | $48M | $52M | $28M | $11M | $331.0K | $5M | $5M | $4M | $3M | $464.0K | $174.0K | $108.0K | |
| Pretax Income | · | · | · | · | · | · | · | $-106M | $-128M | $16M | $-38M | $-15M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| EPS (Basic) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.41 | $-0.97 | $-0.41 | |
| EPS (Diluted) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.39 | $-0.97 | $-0.41 | |
| Shares (Basic) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 39,943,000 | 38,814,000 | 35,709,000 | |
| Shares (Diluted) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 42,561,000 | 38,814,000 | 35,709,000 | |
| EBITDA | $-602M | $-527M | $-484M | $-318M | $-184M | $-92M | $-98M | $-88M | $-111M | $19M | $-37M | $-14M |
Bilanz 26
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $123M | $95M | $113M | $66M | $113M | $83M | $36M | $42M | $125M | $67M | $65M | $20M | |
| Receivables | $18M | $17M | $1M | $147.0K | $52M | $4M | $5M | $2M | $1M | $24.0K | · | · | |
| Inventory | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $17M | $15M | $12M | $12M | $12M | $6M | $3M | $2M | $4M | $2M | $2M | $1M | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Current Assets | $917M | $1.11B | $628M | $795M | $536M | $474M | $234M | $208M | $274M | $159M | $113M | $131M | |
| PP&E (Net) | $79M | $66M | $69M | $80M | $73M | $13M | $5M | $3M | $4M | $4M | $2M | $2M | |
| PP&E (Gross) | $126M | $103M | $97M | $98M | $89M | $38M | $29M | $27M | $26M | $25M | $23M | $22M | |
| Accum. Depreciation | $47M | $37M | $28M | $17M | $16M | $25M | $24M | $24M | $23M | $21M | $21M | $20M | |
| Other Non-current Assets | $17M | $8M | $8M | $10M | $7M | $6M | · | $300.0K | $429.0K | $200.0K | $200.0K | $200.0K | |
| Total Assets | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Accounts Payable | $22M | $20M | $22M | $26M | $21M | $8M | $8M | $4M | $5M | $4M | $2M | $1M | |
| Accrued Liabilities | $83M | $55M | $43M | $44M | $34M | $19M | $12M | $16M | $17M | $18M | $8M | $5M | |
| Current Liabilities | $202M | $180M | $103M | $85M | $72M | $31M | $26M | $22M | $32M | $33M | $32M | $24M | |
| Capital Leases | $108M | $113M | $120M | $127M | $112M | $440.0K | $2M | $771.0K | · | · | · | · | |
| Other Non-current Liabilities | · | $0 | $186.0K | $1M | $4M | $0 | · | $771.0K | $1M | $142.0K | · | · | |
| Total Liabilities | $2.08B | $1.54B | $1.21B | $1.12B | $597M | $420M | $301M | $185M | $185M | $76M | $47M | $41M | |
| Long-term Debt | $288M | $620M | $639M | $650M | · | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Total Debt | $288M | $105M | $68M | $64M | $47M | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Common Stock | $123.0K | $118.0K | $102.0K | $94.0K | $84.0K | $70.0K | $59.0K | $55.0K | $54.0K | $41.0K | $40.0K | $39.0K | |
| Paid-in Capital | · | · | · | · | $1.45B | · | · | · | · | · | · | $589M | |
| Retained Earnings | $-3.49B | $-2.70B | $-2.11B | $-1.59B | $-1.21B | $-992M | $-865M | $-743M | $-646M | $-518M | $-535M | $-497M | |
| AOCI | $630.0K | $2M | $-10.0K | $-4M | $-869.0K | $149.0K | $679.0K | $500.0K | $343.0K | $137.0K | $149.0K | $-4.0K | |
| Stockholders' Equity | $-660M | $-135M | $-386M | $-108M | $244M | $113M | $-11M | $26M | $110M | $94M | $69M | $92M | |
| Liabilities + Equity | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Shares Outstanding | 122,943,172 | 118,209,139 | 101,637,922 | 94,833,975 | 84,799,542 | 71,015,183 | 59,172,124 | 54,717,906 | 53,960,832 | 40,646,595 | 39,581,692 | 38,659,738 |
Cashflow 16
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $10M | $10M | $12M | $6M | $2M | $2M | $1M | $1M | $2M | $741.0K | $589.0K | $490.0K | |
| Stock-based Comp | $112M | $98M | $72M | $48M | $27M | $18M | $11M | $10M | $9M | $7M | $5M | $3M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Other Non-cash | $153M | $86M | $28M | $36M | $44M | $117M | $19M | $-6M | $15M | $13M | $37M | $-34M | |
| Operating Cash Flow | $-510M | $-396M | $-414M | $-300M | $-143M | $9M | $-91M | $-101M | $-102M | $37M | $5M | $-45M | |
| CapEx | $25M | $4M | $1M | $11M | $49M | $11M | $3M | $889.0K | $3M | $2M | $562.0K | $1M | |
| Investing Cash Flow | $17M | $-553M | $239M | $-262M | $-148M | $-197M | $-75M | $5M | $-66M | · | · | · | |
| Net Debt Issued | $-11M | $-9M | · | $-48M | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Net Stock Activity | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Financing Cash Flow | $524M | $931M | $221M | $516M | $320M | $234M | $160M | $13M | $226M | · | · | · | |
| Net Change in Cash | $30M | $-18M | $46M | $-45M | $30M | $47M | $-6M | $-83M | $58M | $2M | $45M | $57.0K | |
| Taxes Paid | $0 | $0 | $0 | · | · | · | · | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | |
| Free Cash Flow | $-535M | $-400M | $-416M | $-311M | $-191M | $-2M | $-94M | $-102M | $-105M | $35M | $4M | $-46M | |
| Levered FCF | · | · | · | · | · | · | · | $-106M | $-108M | $33M | · | $-46M |
Rentabilität 7
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% | -168.3% | -368.0% | -282.3% | -848.3% | 17.6% | -130.5% | -31.4% | |
| Net Margin | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | -228.0% | -452.9% | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| Pretax Margin | · | · | · | · | · | · | · | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| EBITDA Margin | -683.9% | -2851.1% | -6431.8% | -336.6% | -261.3% | -165.0% | -363.2% | -278.3% | -833.9% | 18.3% | -128.5% | -30.4% | |
| ROA | -55.5% | -53.0% | -57.2% | -41.9% | -31.3% | -30.9% | -48.6% | -42.0% | -55.0% | 11.5% | -30.2% | -13.6% | |
| ROE | 152.7% | 789.8% | 127.6% | 628.0% | -87.4% | -96.8% | 790.0% | -272.5% | -125.2% | 20.2% | -46.7% | -20.0% | |
| ROIC | · | · | · | · | · | · | · | -130.1% | -80.1% | 15.0% | -44.9% | -16.0% |
Liquidität & Solvenz 5
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 | 15.2 | 9.0 | 9.4 | 8.5 | 4.8 | 3.6 | 5.5 | |
| Quick Ratio | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 | 2.8 | 1.6 | 2.0 | 3.9 | 2.0 | 2.1 | 0.8 | |
| Debt / Equity | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.6 | 0.3 | 0.3 | 0.2 | · | |
| LT Debt / Equity | -0.4 | -0.7 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.5 | 0.3 | 0.3 | 0.2 | · | |
| Interest Coverage | -13.4 | -14.2 | -17.5 | -16.7 | -11.3 | -5.9 | -14.9 | -23.4 | -37.6 | 6.9 | · | · |
Effizienz 2
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.7 | 0.2 | 0.4 | |
| Receivables Turnover | 5.1 | 2.1 | 10.5 | 3.6 | 2.5 | 11.7 | 7.3 | 18.8 | 23.5 | · | · | · |
Wachstumsraten 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 376.6% | 145.3% | -92.0% | 34.3% | 26.2% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -2.4% | -36.0% | -48.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 9.5% | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM) 14
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| Net Income TTM | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| Market Cap | $7.81B | $5.56B | $8.49B | $4.35B | $3.87B | $1.48B | $628M | $346M | $440M | $494M | $414M | $310M | |
| Enterprise Value | $7.98B | $5.57B | $8.44B | $4.34B | $3.80B | $1.44B | $636M | $346M | $346M | $457M | $364M | · | |
| P/E | -9.7 | -8.9 | -15.3 | -10.6 | -16.3 | -10.5 | · | · | -3.1 | 31.2 | -10.8 | -19.5 | |
| P/S | 88.7 | 301.0 | 1126.9 | 45.9 | 54.9 | 26.4 | 23.4 | 11.0 | 32.9 | 4.6 | 14.4 | 6.6 | |
| P/B | -11.8 | -41.1 | -22.0 | -40.3 | 15.8 | 13.0 | -57.4 | 13.3 | 4.0 | 5.2 | 6.0 | 3.4 | |
| P / Tangible Book | · | · | · | · | 15.8 | 13.0 | · | · | · | · | · | · | |
| P / Cash Flow | -15.3 | -14.0 | -20.5 | -14.5 | -27.1 | 165.0 | -6.9 | -3.4 | -4.3 | 13.4 | 84.8 | -6.9 | |
| P / FCF | -14.6 | -13.9 | -20.4 | -14.0 | -20.2 | -699.7 | -6.7 | -3.4 | -4.2 | 14.0 | 95.8 | -6.7 | |
| EV / EBITDA | -13.2 | -10.6 | -17.4 | -13.6 | -20.6 | -15.6 | -6.5 | -3.9 | -3.1 | 23.5 | -9.9 | · | |
| EV / FCF | -14.9 | -13.9 | -20.3 | -14.0 | -19.9 | -682.3 | -6.8 | -3.4 | -3.3 | 12.9 | 84.1 | · | |
| EV / Revenue | 90.6 | 301.5 | 1121.0 | 45.9 | 54.0 | 25.8 | 23.7 | 11.0 | 25.9 | 4.3 | 12.7 | · | |
| Earnings Yield | -10.3% | -11.2% | -6.5% | -9.4% | -6.1% | -9.5% | · | · | -31.8% | 3.2% | -9.3% | -5.1% |
Gewinn- und Verlustrechnung 14
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29M | $19M | $18M | $2M | $67M | $2M | $17M | $463.0K | $249.0K | $835.0K | $2M | $378.0K | $867.0K | $5M | $2M | $3M | |
| R&D Expense | $98M | $96M | $104M | $99M | $110M | $98M | $94M | $85M | $80M | $82M | $85M | $83M | $83M | $79M | $75M | $63M | |
| SG&A Expense | $104M | $105M | $92M | $69M | $66M | $57M | $62M | $57M | $51M | $46M | $44M | $40M | $40M | $50M | $54M | $48M | |
| Operating Expenses | $208M | $203M | $196M | $169M | $178M | $157M | $156M | $141M | $130M | $127M | $129M | $123M | $123M | $129M | $129M | $111M | |
| Operating Income | $-179M | $-184M | $-178M | $-167M | $-112M | $-156M | $-139M | $-141M | $-130M | $-126M | $-127M | $-122M | $-122M | $-124M | $-127M | $-108M | |
| Interest Expense | · | · | $14M | $11M | $11M | · | $9M | $9M | $13M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $4M | |
| Other Non-op | $14M | $11M | $11M | $10M | $13M | $14M | $15M | $17M | $12M | $8M | $8M | $7M | $7M | $6M | $6M | $4M | |
| Net Income | $-199M | $-206M | $-183M | $-306M | $-134M | $-161M | $-150M | $-161M | $-143M | $-136M | $-137M | $-129M | $-129M | $-131M | $-137M | $-142M | |
| EPS (Basic) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| EPS (Diluted) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| Shares (Basic) | 132,086 | 123,273 | -237,832 | 119,982 | 119,457 | 118,496 | -216,870 | 117,685 | 109,240 | 101,924 | -190,466 | 96,071 | 95,755 | 95,164 | -174,660 | 93,758 | |
| Shares (Diluted) | 132,086 | 123,273 | -237,832 | 119,982 | 119,457 | 118,496 | -216,870 | 117,685 | 109,240 | 101,924 | -190,466 | 96,071 | 95,755 | 95,164 | -174,660 | 93,758 | |
| EBITDA | $-179M | $-180M | · | $-167M | $-112M | $-153M | · | $-141M | $-130M | $-124M | · | $-122M | $-122M | $-123M | · | $-108M |
Bilanz 24
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $255M | $130M | $123M | $225M | $75M | $74M | $95M | $47M | $190M | $120M | · | $100M | $69M | $102M | · | $106M | |
| Receivables | $24M | $7M | $18M | $2M | $8M | $2M | $17M | $244.0K | $0 | $834.0K | · | $2M | $985.0K | $1M | · | $2M | |
| Inventory | $380.0K | $154.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $14M | $17M | $13M | $20M | $16M | $15M | $7M | $11M | $19M | · | $20M | $20M | $16M | · | $14M | |
| Current Assets | $1.21B | $839M | $917M | $977M | $887M | $956M | $1.11B | $1.02B | $1.07B | $639M | · | $561M | $587M | $681M | · | $884M | |
| PP&E (Net) | $79M | $82M | $79M | $76M | $70M | $67M | $66M | $64M | $66M | $68M | · | $76M | $77M | $79M | · | $80M | |
| PP&E (Gross) | · | · | $126M | · | · | · | $103M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $37M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $19M | $18M | $17M | $17M | $15M | $13M | $8M | $8M | $8M | $8M | · | $8M | $8M | $8M | · | · | |
| Total Assets | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Accounts Payable | $21M | $25M | $22M | $22M | $16M | $14M | $20M | $12M | $9M | $13M | · | $14M | $13M | $17M | · | $14M | |
| Accrued Liabilities | $77M | $69M | $83M | $62M | $52M | $43M | $55M | $50M | $40M | $40M | · | $33M | $31M | $36M | · | $40M | |
| Current Liabilities | $181M | $199M | $202M | $142M | $131M | $160M | $180M | $110M | $103M | $89M | · | $78M | $66M | $75M | · | $76M | |
| Capital Leases | $102M | $105M | $108M | $111M | $111M | $113M | $113M | $115M | $117M | $119M | · | $122M | $124M | $125M | · | $114M | |
| Other Non-current Liabilities | · | · | · | $2M | $2M | $3M | · | $0 | $0 | $2.0K | · | $408.0K | $625.0K | $837.0K | · | $1M | |
| Total Liabilities | $2.10B | $2.10B | $2.08B | $1.96B | $1.59B | $1.53B | $1.54B | $1.45B | $1.42B | $1.20B | · | $1.18B | $1.11B | $1.12B | · | $1.09B | |
| Long-term Debt | $276M | $292M | $288M | $1.00B | $610M | $610M | $105M | $620M | $629M | $630M | · | · | · | · | · | · | |
| Total Debt | $276M | $292M | · | $176M | $173M | $105M | · | $105M | $104M | $68M | · | $61M | $62M | $64M | · | $64M | |
| Common Stock | $138.0K | $124.0K | $123.0K | $122.0K | $119.0K | $119.0K | $118.0K | $118.0K | $117.0K | $105.0K | · | $94.0K | $94.0K | $94.0K | · | $93.0K | |
| Retained Earnings | $-3.89B | $-3.69B | $-3.49B | $-3.30B | $-3.00B | $-2.86B | $-2.70B | $-2.55B | $-2.39B | $-2.25B | · | $-1.98B | $-1.85B | $-1.72B | · | $-1.45B | |
| AOCI | $-4M | $-2M | $630.0K | $34.0K | $-158.0K | $2M | $2M | $5M | $-1M | $-539.0K | · | $-874.0K | $-1M | $-2M | · | $-6M | |
| Stockholders' Equity | $-173M | $-827M | $-660M | $-521M | $-369M | $-266M | $-135M | $-14M | $109M | $-396M | $-386M | $-439M | $-333M | $-229M | $-108M | $-16M | |
| Liabilities + Equity | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Shares Outstanding | · | · | 122,943,172 | · | · | · | 118,209,139 | · | · | · | · | · | · | · | · | · |
Cashflow 12
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $2M | $2M | $2M | $2M | $1M | |
| Stock-based Comp | $36M | $30M | $31M | $31M | $28M | $24M | $26M | $25M | $25M | $22M | $19M | $19M | $19M | $15M | $13M | $13M | |
| Other Non-cash | · | $27M | · | · | · | $4M | · | · | · | $-18M | · | · | · | $-8M | · | · | |
| Operating Cash Flow | $-160M | $-145M | $-143M | $-108M | $-128M | $-132M | $-66M | $-102M | $-99M | $-130M | $-74M | $-96M | $-122M | $-122M | $-98M | $-84M | |
| CapEx | $4M | $6M | $6M | $9M | $4M | $6M | $1M | $701.0K | $2M | $0 | $77.0K | $220.0K | $717.0K | $402.0K | $3M | $6M | |
| Investing Cash Flow | $-507M | $145M | $-71M | $-71M | $53M | $106M | $111M | $-45M | $-652M | $33M | $-81M | $73M | $82M | $165M | $29M | $-292M | |
| Net Debt Issued | · | $-3M | · | · | · | $-3M | · | · | · | $-705.0K | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | $0 | $0 | · | · | · | $94M | · | · | · | $0 | · | · | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $94M | · | · | · | · | · | · | |
| Financing Cash Flow | $793M | $8M | $111M | $330M | $79M | $5M | $2M | $3M | $821M | $104M | $169M | $54M | $5M | $-7M | $30M | $389M | |
| Net Change in Cash | $125M | $7M | $-103M | $152M | $2M | $-21M | $48M | $-143M | $70M | $7M | $13M | $31M | $-34M | $36M | $-39M | $13M | |
| Free Cash Flow | · | $-151M | · | · | · | $-137M | · | · | · | $-130M | · | · | · | $-123M | · | · |
Rentabilität 5
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -626.0% | -948.7% | · | -8613.4% | -167.0% | -9856.3% | · | -30410.6% | -52277.9% | -15118.0% | · | -32345.2% | -14077.2% | -2698.3% | · | -4311.8% | |
| Net Margin | -694.4% | -1064.5% | · | -15815.0% | -201.3% | -10220.1% | · | -34675.0% | -57557.4% | -16244.7% | · | -34238.6% | -14837.0% | -2846.1% | · | -5658.4% | |
| EBITDA Margin | -626.0% | -931.2% | · | -8613.4% | -167.0% | -9710.6% | · | -30410.6% | -52277.9% | -14838.8% | · | -32345.2% | -14077.2% | -2658.2% | · | -4311.8% | |
| ROA | -12.6% | -16.2% | · | -21.3% | -9.8% | -15.6% | · | -14.8% | -12.4% | -16.0% | · | -14.2% | -16.6% | -15.0% | · | -14.9% | |
| ROE | 73.3% | 37.7% | · | 114.5% | 103.3% | 48.7% | · | 70.9% | 127.6% | 43.4% | · | 56.9% | 116.1% | 232.9% | · | -122.1% |
Liquidität & Solvenz 5
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.7 | 4.2 | · | 6.9 | 6.8 | 6.0 | · | 9.3 | 10.4 | 7.2 | · | 7.2 | 8.9 | 9.0 | · | 11.6 | |
| Quick Ratio | 1.5 | 0.7 | · | 1.6 | 0.6 | 0.5 | · | 0.4 | 1.9 | 1.4 | · | 1.3 | 1.1 | 1.4 | · | 1.4 | |
| Debt / Equity | -1.6 | -0.4 | · | -0.3 | -0.5 | -0.4 | · | -7.5 | 1.0 | -0.2 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| LT Debt / Equity | -1.4 | -0.3 | · | -0.3 | -0.4 | -0.3 | · | -6.7 | 0.9 | -0.1 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| Interest Coverage | · | · | · | -14.7 | -10.1 | · | · | -15.8 | -10.2 | -17.8 | · | -17.1 | -17.3 | -17.9 | · | -15.9 |
Effizienz 2
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.7 | 4.4 | · | 1.9 | 15.9 | 1.1 | · | 0.3 | 0.5 | 0.9 | · | 0.2 | 0.6 | 1.3 | · | 1.7 |
Bewertung (TTM) 4
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $117M | $90M | · | $71M | $69M | $3M | · | $2M | $2M | $7M | · | $8M | $97M | $97M | · | $98M | |
| Net Income TTM | $-845M | $-808M | · | $-762M | $-600M | $-601M | · | $-569M | $-537M | $-525M | · | $-532M | $-422M | $-383M | · | $-328M | |
| P/E | -12.5 | -9.8 | · | -8.6 | -6.4 | -7.5 | · | -9.9 | -10.2 | -13.0 | · | -5.3 | -7.3 | -8.4 | · | -12.9 | |
| Earnings Yield | -8.0% | -10.2% | · | -11.6% | -15.6% | -13.3% | · | -10.1% | -9.8% | -7.7% | · | -19.0% | -13.7% | -11.9% | · | -7.7% |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Umsatz | $88M | $18M | $8M | $95M | $70M |
| Betriebsgewinnmarge % | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% |
| Nettoergebnis | $-785M | $-590M | $-526M | $-389M | $-215M |
| Verwässerte EPS | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 |
| Liquiditätsgrad | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 |
| Quick Ratio | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 |
Cashflow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Freier Cashflow | $-535M | $-400M | $-416M | $-311M | $-191M |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 539 Einreicher · $9.0B gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 95 (-9 vs. Vorquartal) | 49 (-6 vs. Vorquartal) | 230 (+51 vs. Vorquartal) | 112 (-32 vs. Vorquartal) | +5.3M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| VANGUARD PORTFOLIO MANAGEMENT LLC | $571.778.157 | 6.711.799 | 6,37% | Aktien |
| STATE STREET CORP | $553.243.709 | 6.494.233 | 6,16% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $521.151.103 | 6.117.515 | 5,80% | Aktien |
| WELLINGTON MANAGEMENT GROUP LLP | $509.521.049 | 5.980.996 | 5,67% | Aktien |
| Avoro Capital Advisors LLC | $425.949.915 | 4.999.999 | 4,74% | Aktien |
| FMR LLC | $375.035.430 | 4.402.341 | 4,18% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $259.207.450 | 3.042.018 | 2,89% | Aktien |
| BANK OF AMERICA CORP /DE/ | $251.706.463 | 2.954.648 | 2,80% | Aktien |
| RTW INVESTMENTS, LP | $243.814.036 | 2.862.003 | 2,72% | Aktien |
| Polar Capital Holdings Plc | $191.988.358 | 2.253.649 | 2,14% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $161.060.214 | 1.890.600 | 1,79% | Kaufoption |
| Capital Research Global Investors | $143.683.584 | 1.686.625 | 1,60% | Aktien |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $136.597.224 | 1.603.442 | 1,52% | Aktien |
| Integral Health Asset Management, LLC | $136.304.000 | 1.600.000 | 1,52% | Aktien |
| Point72 Asset Management, L.P. | $135.257.185 | 1.587.712 | 1,51% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $133.386.924 | 1.565.758 | 1,49% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $131.998.327 | 1.549.458 | 1,47% | Aktien |
| PRINCIPAL FINANCIAL GROUP INC | $111.435.932 | 1.308.087 | 1,24% | Aktien |
| Capital International Investors | $111.245.191 | 1.305.848 | 1,24% | Aktien |
| ARMISTICE CAPITAL, LLC | $106.487.500 | 1.250.000 | 1,19% | Kaufoption |
| ARMISTICE CAPITAL, LLC | $102.342.325 | 1.201.342 | 1,14% | Aktien |
| Pictet Asset Management Holding SA | $99.038.455 | 1.160.463 | 1,10% | Aktien |
| Frazier Life Sciences Management, L.P. | $98.810.092 | 1.159.879 | 1,10% | Aktien |
| Holocene Advisors, LP | $97.506.685 | 1.144.579 | 1,09% | Aktien |
| Woodline Partners LP | $93.769.315 | 1.100.708 | 1,04% | Aktien |
| NORGES BANK | $86.512.319 | 1.015.522 | 0,96% | Aktien |
| Royalty Pharma Sub-Manager, LLC | $83.519.594 | 980.392 | 0,93% | Aktien |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $81.937.000 | 961.815 | 0,91% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $77.218.175 | 906.423 | 0,86% | Aktien |
| CITADEL ADVISORS LLC | $77.062.874 | 904.600 | 0,86% | Kaufoption |
| Melqart Asset Management (UK) Ltd | $65.385.455 | 767.525 | 0,73% | Aktien |
| Siren, L.L.C. | $64.655.121 | 758.952 | 0,72% | Aktien |
| Fisher Asset Management, LLC | $63.355.547 | 743.697 | 0,71% | Aktien |
| Foresite Capital Management IV, LLC | $60.884.867 | 714.695 | 0,68% | Aktien |
| Balyasny Asset Management L.P. | $60.599.821 | 711.349 | 0,67% | Aktien |
| Deep Track Capital, LP | $59.633.000 | 700.000 | 0,66% | Aktien |
| JANE STREET GROUP, LLC | $59.633.000 | 700.000 | 0,66% | Kaufoption |
| BNP PARIBAS FINANCIAL MARKETS | $58.702.470 | 689.077 | 0,65% | Aktien |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | $56.251.809 | 660.310 | 0,63% | Aktien |
| CITADEL ADVISORS LLC | $54.601.338 | 640.936 | 0,61% | Aktien |
| GOLDMAN SACHS GROUP INC | $54.053.311 | 634.503 | 0,60% | Aktien |
| Qube Research & Technologies Ltd | $48.774.257 | 572.535 | 0,54% | Aktien |
| EVENTIDE ASSET MANAGEMENT, LLC | $48.081.832 | 564.398 | 0,54% | Aktien |
| Affinity Asset Advisors, LLC | $46.854.500 | 550.000 | 0,52% | Aktien |
| First Turn Management, LLC | $44.930.228 | 527.412 | 0,50% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $44.162.525 | 518.398 | 0,49% | Aktien |
| Caption Management, LLC | $43.651.356 | 512.400 | 0,49% | Kaufoption |
| D. E. Shaw & Co., Inc. | $40.874.247 | 479.801 | 0,46% | Aktien |
| Checkpoint Capital L.P. | $40.465.250 | 475.000 | 0,45% | Aktien |
| Hood River Capital Management LLC | $39.977.367 | 469.273 | 0,45% | Aktien |
| RP Management, LLC | $39.401.954 | 980.392 | 0,44% | Aktien |
| EMERALD ADVISERS, LLC | $39.013.272 | 457.956 | 0,43% | Aktien |
| ADAR1 Capital Management, LLC | $39.009.097 | 457.907 | 0,43% | Aktien |
| AMERIPRISE FINANCIAL INC | $38.010.006 | 446.179 | 0,42% | Aktien |
| Candriam S.C.A. | $37.708.477 | 443.066 | 0,42% | Aktien |
| MARSHALL WACE, LLP | $36.259.335 | 425.629 | 0,40% | Aktien |
| RHUMBLINE ADVISERS | $35.933.015 | 421.799 | 0,40% | Aktien |
| CITADEL ADVISORS LLC | $35.882.028 | 421.200 | 0,40% | Verkaufsoption |
| ALLIANCEBERNSTEIN L.P. | $35.327.299 | 535.993 | 0,39% | Aktien |
| GILDER GAGNON HOWE & CO LLC | $34.096.829 | 400.245 | 0,38% | Aktien |
| TD Asset Management Inc | $32.809.225 | 385.130 | 0,37% | Aktien |
| BlackRock, Inc. | $29.124.928 | 341.882 | 0,32% | Aktien |
| GSK plc | $29.001.573 | 340.434 | 0,32% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $27.040.243 | 317.411 | 0,30% | Aktien |
| CITIGROUP INC | $26.852.314 | 315.205 | 0,30% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $24.671.024 | 289.600 | 0,27% | Verkaufsoption |
| Trails Edge Capital Partners, LP | $24.542.302 | 288.089 | 0,27% | Aktien |
| EMERALD MUTUAL FUND ADVISERS TRUST | $23.833.521 | 279.769 | 0,27% | Aktien |
| Polaris Capital Management, LLC | $22.737.211 | 266.900 | 0,25% | Aktien |
| SEGALL BRYANT & HAMILL, LLC | $21.899.197 | 257.063 | 0,24% | Aktien |
| Alyeska Investment Group, L.P. | $21.297.500 | 250.000 | 0,24% | Aktien |
| ExodusPoint Capital Management, LP | $21.234.374 | 249.259 | 0,24% | Aktien |
| Capital World Investors | $21.196.550 | 248.815 | 0,24% | Aktien |
| Walleye Capital LLC | $20.422.428 | 239.728 | 0,23% | Aktien |
| E. Ohman J:or Asset Management AB | $19.823.223 | 300.762 | 0,22% | Aktien |
| Sarissa Capital Management LP | $19.476.393 | 228.623 | 0,22% | Aktien |
| Swiss National Bank | $18.946.256 | 222.400 | 0,21% | Aktien |
| SPHERA FUNDS MANAGEMENT LTD. | $18.740.693 | 219.987 | 0,21% | Aktien |
| BAKER BROS. ADVISORS LP | $17.997.836 | 211.267 | 0,20% | Aktien |
| California Public Employees Retirement System | $17.979.520 | 211.052 | 0,20% | Aktien |
| Nicholas Investment Partners, LP | $17.810.758 | 209.071 | 0,20% | Aktien |
| PINNACLE ASSOCIATES LTD | $17.245.864 | 202.440 | 0,19% | Aktien |
| Mirador Capital Partners LP | $17.239.900 | 202.370 | 0,19% | Aktien |
| Tri Locum Partners LP | $16.526.860 | 194.000 | 0,18% | Aktien |
| PFM Health Sciences, LP | $16.329.730 | 191.686 | 0,18% | Aktien |
| Rock Springs Capital Management LP | $16.014.016 | 187.980 | 0,18% | Aktien |
| PRUDENTIAL FINANCIAL INC | $15.933.512 | 187.035 | 0,18% | Aktien |
| DAFNA Capital Management LLC | $14.652.510 | 171.998 | 0,16% | Aktien |
| Ghisallo Capital Management LLC | $14.482.300 | 170.000 | 0,16% | Aktien |
| Impax Asset Management Group plc | $14.056.350 | 165.000 | 0,16% | Aktien |
| Lombard Odier Asset Management (Europe) Ltd | $13.494.096 | 158.400 | 0,15% | Kaufoption |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | $13.383.349 | 157.100 | 0,15% | Aktien |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $13.330.276 | 156.477 | 0,15% | Aktien |
| JANE STREET GROUP, LLC | $12.735.905 | 149.500 | 0,14% | Verkaufsoption |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $12.145.719 | 139.190 | 0,14% | Aktien |
| Retirement Systems of Alabama | $11.962.891 | 140.426 | 0,13% | Aktien |
| MetLife Investment Management, LLC | $11.930.519 | 140.046 | 0,13% | Aktien |
| Polymer Capital Management (HK) LTD | $11.777.943 | 138.255 | 0,13% | Aktien |
| Cinctive Capital Management LP | $11.742.419 | 137.838 | 0,13% | Aktien |
| TUDOR INVESTMENT CORP ET AL | $11.279.156 | 132.400 | 0,13% | Kaufoption |
Unternehmensinsider 52 Insider · 18 Führungskräfte · 22 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Sung Lee | EVP, Chief Financial Officer | 1. Juli 2026 M | 63.221 | 0 | 5 | $-5.695.855 |
| Ching Jaw | SVP Finance & CFO | 6. März 2023 A | 87.346 | 0 | 0 | $0 |
| Sharon Surrey Barbari | EVP, Finance & CFO | 28. Februar 2017 F | 40.323 | 0 | 0 | $0 |
| Fady Ibraham Malik | EVP Research & Development | 18. August 2026 M | 153.902 | 0 | 21 | $-4.352.750 |
| Andrew Callos | EVP, Chief Commercial Officer | 30. Juli 2026 M | 58.555 | 0 | 24 | $-15.318.893 |
| Jeffrey Hessekiel | Chief Legal & Admin Officer | 15. März 2026 A | 107.943 | 0 | 0 | $0 |
| Robert Wong | VP, Chief Accounting Officer | 3. Dezember 2024 A | 18.655 | 0 | 0 | $0 |
| Brett A Pletcher | EVP, Chief Legal Officer | 30. August 2024 A | 33.140 | 0 | 0 | $0 |
| Mark A Schlossberg | SVP - Legal & General Counsel | 15. März 2022 M | 103.408 | 0 | 0 | $0 |
| David Cragg | Chief HR & Admin Officer | 7. März 2022 F | 153.233 | 0 | 0 | $0 |
| Caryn Gordon Mcdowell | GC & Chief Compliance Officer | 27. Februar 2018 A | 32.548 | 0 | 0 | $0 |
| Peter S Roddy | SVP Finance & CAO | 27. Februar 2018 A | 21.520 | 0 | 0 | $0 |
| Bradley Paul Morgan | SVP Drug Discovery & Early Dev | 31. August 2017 M | 46.441 | 0 | 0 | $0 |
| Bonnie Charpentier | SVP Regulatory & Compliance | 28. Februar 2017 A | 29.004 | 0 | 0 | $0 |
| Andrew A Wolff | SVP & CMO | 28. Februar 2017 A | 47.255 | 0 | 0 | $0 |
| David J Morgans JR | EVP-Preclinical R&D | 28. Februar 2011 A | 42.000 | 0 | 0 | $0 |
| Michael Rabson | SVP Business Dev/Legal & GC | 18. Dezember 2009 M | 20.043 | 0 | 0 | $0 |
| Jay K Trautman | VP, Discovery Research | 29. Februar 2008 A | 47.896 | 0 | 0 | $0 |
| Robert Arthur Harrington | Direktor | 15. Juli 2026 A | 21.932 | 0 | 2 | $-248.260 |
| James M Daly | Direktor | 15. Juli 2026 A | 3.390 | 0 | 0 | $0 |
| Edward M. Kaye MD | Direktor | 15. Juli 2026 A | 10.434 | 0 | 6 | $-3.544.372 |
| Nancy Wysenski | Direktor | 15. Juli 2026 A | 33.992 | 0 | 0 | $0 |
| Wendell Wierenga | Direktor | 15. Juli 2026 A | 35.563 | 0 | 3 | $-1.881.925 |
| John T Henderson | Direktor | 15. Juli 2026 A | 78.360 | 0 | 2 | $-2.078.525 |
| Lynne B Parshall | Direktor | 1. Juni 2026 S | 15.784 | 0 | 3 | $-1.000.100 |
| Muna Bhanji | Direktor | 27. Mai 2026 A | 26.361 | 0 | 0 | $0 |
| Robert E Landry | Direktor | 27. Mai 2026 A | 10.184 | 0 | 0 | $0 |
| Wendall Wierenga | Direktor | 15. Juli 2025 A | 32.345 | 0 | 0 | $0 |
| COSTA SANTO J | Direktor | 15. Mai 2024 A | 20.600 | 0 | 0 | $0 |
| Sandford D Smith | Direktor | 2. Januar 2024 A | 18.801 | 0 | 0 | $0 |
| Robert Califf | Direktor | 3. Januar 2022 A | 6.003 | 0 | 0 | $0 |
| GAGE L PATRICK | Direktor | 8. November 2021 M | 28.932 | 0 | 0 | $0 |
| Denise Gilbert | Direktor | 20. Mai 2015 J | — | 0 | 0 | $0 |
| Stephen M Dow | Direktor | 2. Januar 2013 A | 1.421.052 | 0 | 0 | $0 |
| James A Spudich | Direktor | 18. Mai 2011 A | 180.600 | 0 | 0 | $0 |
| Grant A Heidrich III | Direktor | 3. Januar 2011 A | 93.755 | 0 | 0 | $0 |
| Michael Schmertzler | Direktor | 3. Juni 2010 S | 4.340.923 | 0 | 0 | $0 |
| Mark Mcdade | Direktor | 21. Mai 2009 A | — | 0 | 0 | $0 |
| Charles J Homcy | Direktor | 22. Mai 2008 A | — | 0 | 0 | $0 |
| William J Rutter | Direktor | 29. April 2004 C | 172.413 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VI LP | 10%-Eigentümer | 29. April 2004 C | 1.615.716 | 0 | 0 | $0 |
| SRB ASSOCIATES VIII LP | 10%-Eigentümer | 29. April 2004 C | 771.052 | 0 | 0 | $0 |
| SRB ASSOCIATES VII LP | 10%-Eigentümer | 29. April 2004 C | 650.000 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VIII LP | 10%-Eigentümer | 29. April 2004 C | 755.631 | 0 | 0 | $0 |
| Robert I Blum | — | 10. August 2026 M | 377.820 | 0 | 19 | $-9.702.097 |
| Elisabeth Schnieders | — | 28. Februar 2017 A | 43.919 | 0 | 0 | $0 |
| James H Sabry | — | 3. Juni 2010 M | 0 | 0 | 0 | $0 |
| SEVIN ROSEN VII AFFILIATES FUND LP | — | 29. April 2004 C | 24.050 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VII LP | — | 29. April 2004 C | 625.950 | 0 | 0 | $0 |
| SRB ASSOCIATES VI LP | — | 29. April 2004 C | 1.742.951 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 84 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| LFSC · RBB Fund, Inc. | 3,16% | 43.268 NS | 31. Mai 2026 | N-PORT |
| HRTS · Tema ETF Trust | 2,52% | 17.069 NS | 31. Mai 2026 | N-PORT |
| PTH · Invesco Exchange-Traded Fund Trust | 1,78% | 61.402 SH | 19. August 2026 | Täglich |
| FMED · Fidelity Covington Trust | 1,55% | 8.262 NS | 31. Mai 2026 | N-PORT |
| GDOC · Goldman Sachs ETF Trust | 1,40% | 3.663 NS | 31. Mai 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 1,24% | 189.801 NS | 30. April 2026 | N-PORT |
| JSML · Janus Detroit Street Trust | 0,98% | 48.338 NS | 30. April 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,94% | 76.297 NS | 30. April 2026 | N-PORT |
| BBC · ETFis Series Trust I | 0,75% | 4.355 NS | 30. April 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,68% | 7.501 SH | 19. August 2026 | Täglich |
| IBB · iShares Trust | 0,66% | 884.741 SH | 19. August 2026 | Täglich |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,64% | 102.933 SH | 19. August 2026 | Täglich |
| IWN · iShares Trust | 0,57% | 1.104.827 SH | 19. August 2026 | Täglich |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,51% | 41.612 NS | 30. April 2026 | N-PORT |
| BIB · ProShares Trust | 0,47% | 4.553 NS | 31. Mai 2026 | N-PORT |
| NUSC · Nushares ETF Trust | 0,47% | 94.565 NS | 30. April 2026 | N-PORT |
| MIDE · DBX ETF Trust | 0,41% | 178 NS | 29. Mai 2026 | N-PORT |
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,37% | 22.056 SH | 19. August 2026 | Täglich |
| IQSM · New York Life Investments ETF Trust | 0,34% | 16.959 NS | 30. April 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,34% | 761.130 SH | 19. August 2026 | Täglich |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,33% | 72.343 SH | 19. August 2026 | Täglich |
| VBK · VANGUARD INDEX FUNDS | 0,32% | 1.797.986 SH | 19. August 2026 | Täglich |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,32% | 219.413 SH | 19. August 2026 | Täglich |
| IWM · iShares Trust | 0,31% | 3.379.531 SH | 19. August 2026 | Täglich |
| IVOV · VANGUARD ADMIRAL FUNDS | 0,31% | 53.623 SH | 19. August 2026 | Täglich |
| ISCG · iShares Trust | 0,29% | 38.968 SH | 19. August 2026 | Täglich |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,26% | 55.086 NS | 30. April 2026 | N-PORT |
| ITWO · ProShares Trust | 0,25% | 6.062 NS | 31. Mai 2026 | N-PORT |
| RSSL · Global X Funds | 0,23% | 51.834 NS | 30. April 2026 | N-PORT |
| PTMC · Pacer Funds Trust | 0,23% | 14.028 NS | 30. April 2026 | N-PORT |
| MVV · ProShares Trust | 0,22% | 4.565 NS | 31. Mai 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,21% | 635.330 NS | 31. Mai 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,20% | 19.862 NS | 30. April 2026 | N-PORT |
| ESML · iShares Trust | 0,19% | 72.366 SH | 19. August 2026 | Täglich |
| SCHM · SCHWAB STRATEGIC TRUST | 0,19% | 356.940 NS | 31. Mai 2026 | N-PORT |
| FFSM · FIDELITY COVINGTON TRUST | 0,19% | 37.821 NS | 30. April 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,17% | 40.586 SH | 19. August 2026 | Täglich |
| MIDU · Direxion Shares ETF Trust | 0,15% | 2.025 NS | 30. April 2026 | N-PORT |
| UMDD · ProShares Trust | 0,15% | 638 NS | 31. Mai 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,15% | 11.444 NS | 30. April 2026 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,15% | 47.609 NS | 30. April 2026 | N-PORT |
| UWM · ProShares Trust | 0,15% | 4.765 NS | 31. Mai 2026 | N-PORT |
| ISCB · iShares Trust | 0,15% | 5.565 SH | 19. August 2026 | Täglich |
| SMDX · Tidal Trust III | 0,15% | 2.868 NS | 30. April 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,14% | 3.113.794 SH | 19. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,14% | 333.056 SH | 19. August 2026 | Täglich |
| VXF · VANGUARD INDEX FUNDS | 0,13% | 1.557.779 SH | 19. August 2026 | Täglich |
| FHLC · FIDELITY COVINGTON TRUST | 0,12% | 53.720 NS | 30. April 2026 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,12% | 154 NS | 31. Mai 2026 | N-PORT |
| NBCR · Neuberger Berman ETF Trust | 0,10% | 12.090 NS | 31. Mai 2026 | N-PORT |